Outcome of Board Meeting

28th October 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, C-1, Block G, Exchange Plaza, Dalal Street, Bandra-Kurla Complex, Mumbai - 400 001 Bandra East, Mumbai - 400 051 Scrip Code: 544250 Symbol: SANOFICONR Sub.: Outcome of Board Meeting held on Wednesday, 28th October 2026 Dear Sir/Madam, We refer to our letter dated 22nd October 2026 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 28th October 2026, inter-alia considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026. Further, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we enclose herewith a copy of the Unaudited Financial Results for the quarter and nine months ended 30th September 2026, as approved at the aforesaid meeting, along with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company. In this regard, please also find enclosed the accompanying press release. Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI Listing Regulations. The aforesaid financial results will also be available on the Company's website at https://www.sanofi.com/en/india/consumer- healthcare/investors/financial-results The meeting of Board of Directors commenced at 2:45 p.m. and concluded at 4:30 p.m. Kindly take the above information on record. Thanking you. Yours faithfully, For Sanofi Consumer Healthcare India Limited Nikunjkumar Savaliya Company Secretary and Compliance Officer Membership No.: F7048 Sanofi Consumer Healthcare India Limited, Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, 400079 Tel.: +91(22) 4528 8555 Corporate Identity Number: L21002MH2023PLC402652 website: www.sanofi.in Email: igrc.schil@sanofi.com Price Waterhouse & Co Chartered Accountants LLP Review Report The Board of Directors Sanofi Consumer Healthcare India Limited Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai 400 079. Maharashtra, India 1. We have reviewed the unaudited financial results of Sanofi Consumer Healthcare India Limited (the “Company”) for the quarter ended September 30, 2026 and the year to date results for the period January 1, 2026 to September 30, 2026, which are included in the accompanying ‘Statement of unaudited financial results for the quarter and nine months ended September 30, 2026’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review. 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. 3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West) Mumbai - 400 028 T: +91 (22) 66697508 Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091 Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E) Price Waterhouse & Co Chartered Accountants LLP 5. (a) The financial results of the Company for the quarter ended September 30, 2025 and the year to date results for the period January 1, 2025 to September 30, 2025 were reviewed by another firm of Chartered Accountants who issued their unmodified conclusion, vide their report dated November 12, 2025. (b) The financial statements of the Company for the year ended December 31, 2025 were audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated February 25, 2026. Our conclusion is not modified in respect of these matters. For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/ E-300009 Arunkumar Ramdas Membership Number: 112433 UDIN: 26112433CIXTOW5773 Place: Mumbai Date: October 28, 2026 Sanofi Consumer Healthcare India Limited Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079 Corporate Identity Number: L21002MH2023PLC402652 Tel no: (91-22) 45288555 Website: www.sanofi.in Email: igrc.schil@sanofi.com STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2026 (₹ in Million) Particulars Quarter Quarter Quarter Nine Months Nine Months Year ended ended ended ended ended ended 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.12.2025 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1. Revenue from Operations (Refer note 7) 2,631 2,357 2,339 7,280 6,274 8 ,784 2. Other Income 44 63 3 0 163 138 1 84 3. Total Income (1+2) 2,675 2,420 2 ,369 7 ,443 6 ,412 8 ,968 4. Expenses (a) Cost of Materials Consumed 4 07 4 75 365 1,284 1,108 1,607 (b) Purchases of stock in trade 1 16 1 60 260 457 641 7 02 (c) Changes in Inventories of stock in trade and finished goods 1 21 (72) (7) 2 8 (131) (8) (d) Employee benefits expense 3 07 3 13 317 951 933 1,288 (e) Finance costs 3 4 6 1 2 1 5 20 (f) Depreciation and amortisation expense 31 33 3 3 9 6 8 3 1 17 (g) Other expenses 6 63 5 88 554 1,762 1,531 2,105 Total Expenses 1 ,648 1 ,501 1 ,528 4 ,590 4 ,180 5 ,831 5. Profit before exceptional item and tax (3-4) 1,027 9 19 8 41 2 ,853 2 ,232 3 ,137 6. Exceptional item (Refer note 4) - - - - 6 6 6 6 7. Profit before tax (5+6) 1,027 9 19 841 2,853 2,298 3,203 8. Tax expense Current Tax 2 66 2 34 225 741 579 8 20 Deferred Tax (5) (3) ( 13) ( 20) ( 17) ( 18) 9. Profit for the period/year (7-8) 7 66 6 88 629 2,132 1,736 2,401 10. Other comprehensive income (OCI) Items that will not be reclassified to the statement of profit and loss - Remeasurements of post-employment benefit obligations (11) - - ( 11) - ( 19) - Income Tax impact relating to these items 3 - - 3 - 5 11. Total comprehensive income for the period/year (9+10) 7 58 6 88 629 2,124 1,736 2,387 12. Paid-up equity share capital (Face Value of ₹ 10 per share) 2 30 2 30 2 30 2 30 2 30 2 30 13. [Showing first 8,000 characters — download PDF for full document]